Harris Bell Temin
About Harris Bell Temin
Harris Bell Temin is a Principal Scientist at Bristol Myers Squibb in Cambridge, Massachusetts, with extensive experience in proteomics and drug discovery.
Current Role at Bristol Myers Squibb
Harris Bell Temin is currently a Principal Scientist at Bristol Myers Squibb in Cambridge, Massachusetts. Since assuming this role in 2021, he has been leading a team that focuses on impactful human health research. His work primarily involves advanced applications of proteomics and drug discovery. Temin's expertise in this role is geared towards the identification and characterization of novel biomarkers and drug targets through mass spectrometry-based approaches.
Previous Experience at Bristol Myers Squibb
Before his current role, Harris Bell Temin served as a Senior Research Investigator at Bristol Myers Squibb from 2017 to 2021, also based in Cambridge, Massachusetts. During this period, he honed his skills in mass spectrometry and bioinformatics, playing a significant role in drug discovery and proteomics research. His experience and contributions laid the groundwork for his promotion to Principal Scientist.
Academic Background
Harris Bell Temin has a strong academic background in molecular biology and biology. He earned his Doctor of Philosophy (Ph.D.) in Molecular Biology from the University of South Florida, where he studied from 2010 to 2014. Prior to that, he completed a Bachelor of Science (B.S.) in Biology at the same institution, studying from 2008 to 2009. His doctoral research involved significant development in proteomics, contributing to his expertise in biomarker identification and drug targets.
Early Academic and Research Career
Starting his academic and research journey, Harris Bell Temin worked at the University of South Florida as a Graduate Research Assistant from 2010 to 2014 and as a Teaching Assistant from 2010 to 2012. During this time, he developed a profound understanding of molecular biology and proteomics. Following this, he served as a Postdoctoral Research Scholar at the University of Pittsburgh School of Medicine from 2015 to 2017, where he further specialized in mass spectrometry and bioinformatics.
Expertise in Proteomics and Drug Discovery
Harris Bell Temin is recognized for his extensive experience in the field of proteomics and drug discovery. Skilled in techniques such as Liquid Chromatography-Mass Spectrometry (LC-MS), bioinformatics, and protein chemistry, he has made significant contributions to the identification and characterization of novel biomarkers and drug targets. His work has been instrumental in advancing therapeutic research and development in both academic and industrial settings.